Search

Your search keyword '"Finckh A"' showing total 34 results
Start Over Author "Finckh A" Journal rheumatology
34 results on '"Finckh A"'

1. A potential role for chlamydial infection in rheumatoid arthritis development

Author

Lamacchia, Celine, primary, Aymon, Romain, additional, Hattel, Brian C, additional, Aeby, Sebastien, additional, Kebbi-Beghdadi C, Carole, additional, Gilbert, Benoit, additional, Studer, Olivia, additional, Norris, Jill M, additional, Nolers, Michael V, additional, Demoruelle, M Kristen, additional, Feser, Marie L, additional, Moss, LauraKay, additional, Courvoisier, Delphine S, additional, Lauper, Kim, additional, Deane, Kevin D, additional, Greub G, Gilbert, additional, and Finckh, Axel, additional

Published
2023
Full Text
View/download PDF

3. P188 Baricitinib effectiveness after a previous inadequate response to an alternative JAK inhibitor: results from the Swiss rheumatoid arthritis register

Author

Benoît T. P Gilbert, Delphine S Courvoisier, Denis Mongin, Kim Lauper, Vanessa A Guimaraes, Ruediger B Mueller, and Axel Finckh

Subjects
Rheumatology, Pharmacology (medical)
Abstract

Background/Aims Previous research has suggested that switching between b/tsDMARDs with different mode of action may be more effective than switching agents within the same mechanism of action. Limited data exists about the impact of an inadequate response to a previous JAK-inhibitor (JAKi) on subsequent JAKi effectiveness. Methods This is a nested study within the Swiss Clinical Quality Management (SCQM) registry of RA patients. All patients initiating baricitinib treatment courses (BARI) between 01-09-2017 and 01-06-2020, with at least one follow-up visit, were included. We compared the time to treatment discontinuation, as a measure of drug effectiveness, of BARI with a previous history of an inadequate response (IR) to tofacitinib (“BARI-post-TOFA”) or without (“BARI-initial”). Tofacitinib IR was defined as previous tofacitinib treatment discontinuation for adverse events or for ineffectiveness. Baseline characteristics were compared using t-tests or χ2. We used Kaplan-Meier curve to display crude time to discontinuation and a Cox model to estimate adjusted hazard ratio (HR). Cox model was adjusted for potential confounding factors: age, BMI, concomitant csDMARD, concomitant steroid usage, baseline CDAI, disease duration, smoking status, line of therapy, gender and seropositivity to RF/ACPA. Results Of the 273 included BARI, 72 were initiated in patients with a history of a previous tofacitinib IR (Table 1). No differences were found between the “BARI-post-TOFA” and the “BARI-initial” groups in terms of time-to-discontinuation, as demonstrated by both the unadjusted Kaplan-Meier survival analysis (Log-rank p = 0.44) and the fully adjusted Cox analysis (Hazard Ratio BARI-post-TOFA vs BARI-initial = 0.76 (95% IC [0.42 - 1.34]; p = 0.34). Other covariates significantly associated with drug maintenance were active smoking (p = 0.03) and CDAI score (p < 0.01). Conclusion In this preliminary analysis, a history of prior tofacitinib IR did not appear to significantly impact subsequent drug maintenance of baricitinib. Disclosure B.T.P. Gilbert: Other; Invited speaker for Lilly Symposium SGR Congress Lausanne (2021). D.S. Courvoisier: None. D. Mongin: None. K. Lauper: None. V.A. Guimaraes: Other; Clinical Research Scientist Immunology at Eli Lilly (Suisse) S.A. R.B. Mueller: None. A. Finckh: Grants/research support; Invited speaker and consultant for Eli Lilly. Has received research grant from Eli Lilly.

Published
2022

5. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy

Author

Amstad, Andrea, primary, Papagiannoulis, Eleftherios, additional, Scherer, Almut, additional, Rubbert-Roth, Andrea, additional, Finckh, Axel, additional, Mueller, Ruediger, additional, Dudler, Jean, additional, Möller, Burkhard, additional, Villiger, Peter M, additional, Schulz, Martin M P, additional, and Kyburz, Diego, additional

Published
2022
Full Text
View/download PDF

7. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.

Author

Amstad, Andrea, Papagiannoulis, Eleftherios, Scherer, Almut, Rubbert-Roth, Andrea, Finckh, Axel, Mueller, Ruediger, Dudler, Jean, Möller, Burkhard, Villiger, Peter M, Schulz, Martin M P, and Kyburz, Diego

Subjects
BIOTHERAPY, DRUG efficacy, SCIENTIFIC observation, ANTI-inflammatory agents, JANUS kinases, RHEUMATOID arthritis, DESCRIPTIVE statistics, NEUROTRANSMITTER uptake inhibitors, TERMINATION of treatment, LONGITUDINAL method, PROPORTIONAL hazards models
Abstract

Objectives JAK Inhibitors (JAKi) are recommended DMARDs for patients with moderate-to-severe RA who failed first-line therapy with methotrexate. There is a lack of data allowing an evidence-based choice of subsequent DMARD therapy for patients who had discontinued JAKi treatment. We aimed to compare the effectiveness of TNF inhibitor (TNFi) therapy vs JAKi vs other mode of action (OMA) biologic DMARD (bDMARD) in RA patients who were previously treated with a JAKi. Methods RA patients who discontinued JAKi treatment within the Swiss RA registry SCQM were included for this observational prospective cohort study. The primary outcome was drug retention for either TNFi, OMA bDMARD or JAKi. The hazard ratio for treatment discontinuation was calculated adjusting for potential confounders. A descriptive analysis of the reasons for discontinuation was performed. Results Four hundred treatment courses of JAKi were included, with a subsequent switch to either JAKi, TNFi or OMA bDMARD. The crude overall drug retention was higher in patients switching to another JAKi as compared with TNFi and comparable to OMA. A significant difference of JAKi vs TNFi persisted after adjusting for potential confounders. Conclusion In a real-world population of RA patients who discontinued treatment with a JAKi, switching to another JAKi resulted in a higher drug retention than switching to a TNFi. A switch to a second JAKi seems an effective therapeutic option. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

9. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers

Author

Kearsley-Fleet, Lianne, Závada, Jakub, Hetland, Merete Lund, Nordström, Dan C., Aaltonen, Kalle J., Listing, Joachim, Zink, Angela, Gati, Tamas, Rojkovich, Bernadette, Iannone, Florenzo, Gremese, Elisa, van Riel, Piet L. C. M., van de Laar, Martinus A. F. J., Lie, Elisabeth, Kvien, Tore K., Canhão, Helena, Fonseca, João E., Rotar, Žiga, Loza, Estibaliz, Carmona, Loreto, Askling, Johan, Johansson, Kari, Finckh, Axel, Dixon, William G., and Hyrich, Kimme L.

Published
2015
Full Text
View/download PDF

10. Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the disease

Author

Céline Lamacchia, Jean Villard, Denis Mongin, Axel Finckh, Gaby Palmer, Stéphane Buhler, Zuleika Calderin Sollet, Oliva Studer, Cem Gabay, and Delphine S. Courvoisier

Subjects
Adult, Male, 0301 basic medicine, Time Factors, Receptors, Antigen, T-Cell, alpha-beta, T-Lymphocytes, T cell, Disease, ddc:616.07, Asymptomatic, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Risk Factors, medicine, Humans, T-cell receptor, Pharmacology (medical), Rheumatoid arthritis, Whole blood, ddc:616, 030203 arthritis & rheumatology, business.industry, High-Throughput Nucleotide Sequencing, Middle Aged, medicine.disease, Clone Cells, genomic DNA, Institutional repository, 030104 developmental biology, medicine.anatomical_structure, Asymptomatic Diseases, Immunology, Pre-clinical phases, Female, medicine.symptom, business
Abstract

Objectives To quantitatively profile the T-cell repertoire in the peripheral blood of individuals genetically at risk for RA, namely first-degree relatives of RA patients (RA-FDR) at different phases of disease development. Methods Next-generation sequencing of the TCR CDR3β repertoire was performed on genomic DNA isolated from whole blood samples of RA-FDR selected at three different pre-clinical stages and of matched RA patients (n = 20/group). T-cell clones were identified by their unique sequence and their degree of expansion (frequency) within each sample was characterized. Clones with a frequency over 0.5% were considered highly expanded clones (HEC). Results The absolute number of HEC was significantly higher in established RA patients (mean 4.65) and tended to be higher in symptomatic RA-FDR (mean 3.4) compared with asymptomatic RA-FDR (mean 1.55, P =0.003 and P =0.07, respectively). Asymptomatic individuals with high levels of ACPA did not differ from asymptomatic RA-FDR in terms of absolute number and frequency of clones. The number of HEC tended to be slightly higher at the time of RA onset (P =0.055). Neither clones shared by several patients, nor clones previously associated with RA, were preferentially present within or between the different groups. Finally, a longitudinal analysis did not allow to uncover a kinetic expansion of RA-specific clones closely correlated with disease development. Conclusions HEC were detected in the peripheral blood before the clinical onset of RA, in particular in the later pre-clinical phase of RA development, and their presence increased over time.

Published
2020

16. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries

Author

Courvoisier, Delphine S, primary, Chatzidionysiou, Katarina, additional, Mongin, Denis, additional, Lauper, Kim, additional, Mariette, Xavier, additional, Morel, Jacques, additional, Gottenberg, Jacques-Eric, additional, Bergstra, Sytske Anne, additional, Suarez, Manuel Pombo, additional, Codreanu, Catalin, additional, Kvien, Tore K, additional, Santos, Maria Jose, additional, Pavelka, Karel, additional, Hetland, Merete L, additional, Askling, Johan, additional, Turesson, Carl, additional, Kubo, Satoshi, additional, Tanaka, Yoshiya, additional, Iannone, Florenzo, additional, Choquette, Denis, additional, Nordström, Dan C, additional, Rotar, Ziga, additional, Lukina, Galina, additional, Gabay, Cem, additional, Van Vollenhoven, Ronald, additional, and Finckh, Axel, additional

Published
2020
Full Text
View/download PDF

17. Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritis.

Author

Lamacchia, Celine, Courvoisier, Delphine S, Jarlborg, Matthias, Bas, Sylvette, Roux-Lombard, Pascale, Möller, Burkhard, Ciurea, Adrian, Finckh, Axel, Bentow, Chelsea, Martinez-Prat, Laura, Mahler, Michael, Gabay, Cem, Nissen, Michael J, and Rheumatologists, the SCQM

Subjects
PREDICTIVE tests, IMMUNOGLOBULINS, RHEUMATOID arthritis, IMMUNOENZYME technique
Abstract

Objectives The objective of this study was to analyse the predictive value of anti-carbamylated protein (anti-CarP) and anti-peptidyl-arginine deiminase type-3 (anti-PAD3) antibodies, alone or in combination with RF and ACPA, to identify patients at high risk of developing severe RA outcomes. Methods Patients within the Swiss Clinical Quality Management registry with a biobank sample were tested for RF, ACPA, anti-CarP, and anti-PAD3 antibodies. We examined the association of each autoantibody with DAS28, HAQ and radiographic damage (Ratingen) at baseline and longitudinally. Results Analyses included 851 established RA patients and 516 disease controls [axial spondyloarthritis (axSpA = 320) and PsA (196)]. Anti-CarP and anti-PAD3 antibodies were, respectively, present in 22.4% and 10.7% of the whole RA population, and in 13.2% and 3.8% of the RF and ACPA double seronegative patients. At baseline, RA patients with anti-PAD3 had higher DAS28 (4.2 vs 3.7; P = 0.005) and significantly more radiographic damage (14.9 vs 8.8; P = 0.02) than anti-PAD3-negative patients. In the ACPA-negative subgroup, baseline Ratingen scores were significantly higher in anti-PAD3-positive patients (P = 0.01). The combination of anti-PAD3, RF IgM, and ACPA was associated with significantly higher baseline radiographic scores than the double seropositive group (P = 0.04). The presence of any two of the previous autoantibodies was associated with significantly greater radiographic progression over 10 years than if all were absent (P = 0.02). There were no differences in RA outcome measures with regards to anti-CarP. Conclusions Anti-PAD3 antibodies are associated with higher disease activity and joint damage scores in RA patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

18. Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the disease.

Author

Lamacchia, Céline, Sollet, Zuleika Calderin, Courvoisier, Delphine, Mongin, Denis, Palmer, Gaby, Studer, Oliva, Gabay, Cem, Villard, Jean, Buhler, Stéphane, and Finckh, Axel

Subjects
GENETICS of rheumatoid arthritis, RHEUMATOID arthritis risk factors, SEQUENCE analysis, DNA, CELL receptors, COMPARATIVE studies, DISEASE susceptibility, RHEUMATOID arthritis, DESCRIPTIVE statistics, T cells, BLOOD, SYMPTOMS
Abstract

Objectives To quantitatively profile the T-cell repertoire in the peripheral blood of individuals genetically at risk for RA, namely first-degree relatives of RA patients (RA-FDR) at different phases of disease development. Methods Next-generation sequencing of the TCR CDR3β repertoire was performed on genomic DNA isolated from whole blood samples of RA-FDR selected at three different pre-clinical stages and of matched RA patients (n  = 20/group). T-cell clones were identified by their unique sequence and their degree of expansion (frequency) within each sample was characterized. Clones with a frequency over 0.5% were considered highly expanded clones (HEC). Results The absolute number of HEC was significantly higher in established RA patients (mean 4.65) and tended to be higher in symptomatic RA-FDR (mean 3.4) compared with asymptomatic RA-FDR (mean 1.55, P  =0.003 and P  =0.07, respectively). Asymptomatic individuals with high levels of ACPA did not differ from asymptomatic RA-FDR in terms of absolute number and frequency of clones. The number of HEC tended to be slightly higher at the time of RA onset (P  =0.055). Neither clones shared by several patients, nor clones previously associated with RA, were preferentially present within or between the different groups. Finally, a longitudinal analysis did not allow to uncover a kinetic expansion of RA-specific clones closely correlated with disease development. Conclusions HEC were detected in the peripheral blood before the clinical onset of RA, in particular in the later pre-clinical phase of RA development, and their presence increased over time. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

19. Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution

Author

Lauper, Kim, primary, Mongin, Denis, additional, Alpizar-Rodriguez, Deshire, additional, Codreanu, Catalin, additional, Iannone, Florenzo, additional, Kristianslund, Eirik K, additional, Kvien, Tore K, additional, Pavelka, Karel, additional, Pombo-Suarez, Manuel, additional, Santos, Maria J, additional, Gabay, Cem, additional, Finckh, Axel, additional, and Courvoisier, Delphine S, additional

Published
2019
Full Text
View/download PDF

20. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort

Author

Hendrik Schulze-Koops, Axel Finckh, Rüdiger B. Mueller, T. Kaegi, Johannes von Kempis, Sarah R. Haile, University of Zurich, and Mueller, Rüdiger B

Subjects
Adult, Male, medicine.medical_specialty, 2745 Rheumatology, Radiography, Population, Arthritis, 610 Medicine & health, Late onset, Severity of Illness Index, Arthritis, Rheumatoid, Cohort Studies, Rheumatology, Internal medicine, medicine, Humans, 2736 Pharmacology (medical), Pharmacology (medical), Prospective Studies, Age of Onset, education, Glucocorticoids, Aged, Aged, 80 and over, education.field_of_study, business.industry, Early disease, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), Middle Aged, Prognosis, medicine.disease, Surgery, Antirheumatic Agents, Rheumatoid arthritis, Cohort, Disease Progression, Female, Observational study, business, Switzerland, Follow-Up Studies
Abstract

OBJECTIVE: RA can be categorized into late-onset RA (LORA, >60-65 years) and young-onset RA (YORA, 30-55 years), depending on the patient's age at disease onset. Since the average age of the population is continuously increasing, LORA will most probably gain in importance in the future. Despite this growing importance, LORA has not been the focus of much interest in the past. The aim of this study was to analyse radiographic damage progression of early disease in LORA compared with YORA patients. METHODS: We included all patients from the Swiss RA registry, Swiss Clinical Quality Management in RA, with recent-onset arthritis, either RA (disease duration ≤1 year) or undifferentiated arthritis, as diagnosed by the data-entering physician. Patients were followed for 5 years. The cut-off between YORA and LORA was operationally set at 60 years of age. The primary outcome of this study was disease progression and activity, which was assessed based on the 28-joint DAS (DAS28) and the progression of joint erosions using a validated scoring system (Ratingen score). RESULTS: A total of 592 patients with early disease were analysed. The age at disease onset had a Gaussian distribution, with a single peak at 54 years of age; 366 patients were categorized as YORA and 226 as LORA at disease onset. DAS28 scores were significantly higher among LORA as compared with YORA patients (4.8 vs 4.5, P = 0.049). Corticosteroids were used in 68% of LORA patients as a first-line treatment, compared with 25.4% in YORA patients (χ(2) test: 54.58; P < 0.0001). In contrast, DMARDs were used in 100% of the YORA patients as first-line treatment, compared with 91.2% of the LORA patients. During follow-up, new glucocorticoids, synthetic DMARDs or biologic DMARDs were initiated in 32.8%, 61.1% and 14.1% of all YORA patients and 17.5%, 54.6% and 6.6% of LORA patients, respectively (χ(2) test: 7.08, 22.53, 54.4; all P < 0.01). The DAS28 scores decreased in both groups during the observed time period, and the initial differences in disease activity vanished after 6 months and during the subsequent follow-up. The Ratingen score was higher in LORA than in YORA patients at inclusion (12.7 vs 5.6, P < 0.0001). The rate of radiographic progression at 5 years was similar when comparing LORA and YORA (3.3 vs 2.6, respectively, P = 0.64). The Ratingen scores at onset and during follow-up over 5 years did not clearly separate LORA and YORA into two groups, but rather, increased linearly when comparing the patients in groups per decade from 20 to 92 years of age. CONCLUSION: Our results did not show LORA as a separate subgroup of RA with a different prognosis with regard to radiographic progression.

Published
2013

21. Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years.

Author

Möller, Burkhard, Aletaha, Daniel, Andor, Michael, Atkinson, Andrew, Aubry-Rozier, Bérengère, Brulhart, Laure, Dan, Diana, Finckh, Axel, Grobéty, Véronique, Mandl, Peter, Micheroli, Raphael, Nissen, Michael John, Nydegger, Alexander M, Scherer, Almut, Tamborrini, Giorgio, Ziswiler, Hans-Rudolf, Zufferey, Pascal, and Foundation, and the SONAR group for musculoskeletal ultrasound in the Swiss Clinical Quality Management (SCQM)

Subjects
DOPPLER ultrasonography, ANTIRHEUMATIC agents, LONGITUDINAL method, RHEUMATOID arthritis, SYNOVIAL membranes, ULTRASONIC imaging, SYNOVITIS, QUANTITATIVE research
Abstract

Objectives To evaluate grey scale US (GSUS) and power Doppler US synovitis (PDUS), separately or in combination (CombUS), to predict joint damage progression in RA. Methods In this cohort study nested in the Swiss RA register, all patients with sequential hand radiographs at their first US assessment were included. We analysed the summations of semi-quantitative GSUS, PDUS and CombUS assessments of both wrists and 16 finger joints (maximum 54 points) at their upper limit of normal, their 50th, 75th or 87.5th percentiles for the progression of joint damage (ΔXray). We adjusted for clinical disease activity measures at baseline, the use of biological DMARDs and other confounders. Results After a median of 35 months, 69 of 250 patients with CombUS (28%), 73 of 259 patients with PDUS (28%) and 75 of 287 patients with available GSUS data (26%) demonstrated joint damage progression. PDUS beyond upper limit of normal (1/54), GSUS and CombUS each at their 50th (9/54 and 10/54) and their 75th percentiles (14/54 and 15/54) were significantly associated with ΔXray in crude and adjusted models. In subgroup analyses, GSUS beyond 14/54 and CombUS higher than 15/54 remained significantly associated with ΔXray in patients on biological DMARDs, while clinical disease activity measures had no significant prognostic power in this subgroup. Conclusion Higher levels of GSUS and CombUS are associated with the development of erosions. GSUS appears to be an essential component of synovitis assessment and an independent predictor of joint damage progression in patients on biological DMARDs. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

23. Muscle disorders * 111. The impact of fatigue in patients with idiopathic inflammatory myopathy: a mixed method study

Author

R. Campbell, D. Hofmann, S. Hatch, P. Gordon, H. Lempp, L. Das, P. Blumbergs, V. Limaye, E. Vermaak, N. McHugh, M. H. Edwards, K. Jameson, A. A. Sayer, E. Dennison, C. Cooper, F. B. Salvador, C. Huertas, D. Isenberg, E. J. Jackson, A. Middleton, D. Churchill, K. Walker-Bone, P. R. Worsley, S. Mottram, M. Warner, D. Morrissey, S. Gadola, A. Carr, M. Stokes, R. N. Srivastava, D. Sanghi, A. Elbaz, A. Mor, G. Segal, M. Drexler, D. Norman, E. Peled, N. Rozen, Y. Goryachev, E. M. Debbi, A. Haim, A. Wolf, R. Debi, M. S. Cohen, I. Igolnikov, Y. Bar Ziv, V. Benkovich, B. Bernfeld, J. Collins, R. J. Moots, P. D. Clegg, P. I. Milner, H. D. Ejtehadi, P. N. Nelson, C. Wenham, S. Balamoody, R. Hodgson, P. Conaghan, R. Wilkie, M. Blagojevic, K. P. Jordan, J. Mcbeth, M. J. Peffers, R. J. Beynon, D. J. Thornton, R. Chapman, V. Chapman, D. Walsh, S. Kelly, M. Hui, W. Zhang, S. Doherty, F. Rees, K. Muir, R. Maciewicz, M. Doherty, S. Snelling, R. K. Davidson, T. Swingler, A. Price, I. Clark, E. Stockley, G. Hathway, H. Faas, D. Auer, G. Hirsch, E. Hale, G. Kitas, R. Klocke, A. Abraham, M. S. Pearce, K. D. Mann, R. M. Francis, F. Birrell, M. Tucker, S. J. Mellon, L. Jones, A. J. Price, P. A. Dieppe, H. S. Gill, S. Ashraf, D. A. Walsh, D. McCollum, C. McCabe, S. Grieve, J. Shipley, R. Gorodkin, A. G. Oldroyd, B. Evans, C. Greenbank, M. Bukhari, R. Rajak, C. Bennett, A. Williams, J. C. Martin, R. Abdulkader, C. MacNicol, K. Brixey, S. Stephenson, G. Clunie, R. N. Andrews, E. M. Clark, V. C. Gould, L. Carter, L. Morrison, J. H. Tobias, S. R. Pye, D. Vanderschueren, T. W. O'Neill, D. M. Lee, I. Jans, J. Billen, E. Gielen, M. Laurent, F. Claessens, J. E. Adams, K. A. Ward, G. Bartfai, F. Casanueva, J. D. Finn, G. Forti, A. Giwercman, T. S. Han, I. Huhtaniemi, K. Kula, M. E. Lean, N. Pendleton, M. Punab, F. C. Wu, S. Boonen, C. Mercieca, J. Webb, A. Bhalla, S. Fairbanks, K. E. Moss, C. Collins, P. Sedgwick, J. Parker, N. C. Harvey, Z. A. Cole, S. R. Crozier, G. Ntani, P. A. Mahon, S. M. Robinson, H. M. Inskip, K. M. Godfrey, E. M. Dennison, M. Bridges, S. Ruddick, C. R. Holroyd, P. Mahon, K. Godfrey, T. McNeilly, C. McNally, T. Beringer, M. Finch, A. Coda, J. Davidson, J. Walsh, P. Fowlie, T. Carline, D. Santos, P. Patil, C. Rawcliffe, A. Olaleye, S. Moore, A. Fox, D. Sen, Y. Ioannou, S. Nisar, K. Rankin, M. Birch, S. Finnegan, M. Rooney, D. S. Gibson, A. Malviya, C. M. Ferris, S. P. Rushton, H. E. Foster, H. Hanson, K. Muthumayandi, D. J. Deehan, L. Birt, F. Poland, A. MacGregor, K. Armon, M. Pfeil, F. McErlane, M. W. Beresford, E. M. Baildam, W. Thomson, K. Hyrich, A. Chieng, J. Gardner-Medwin, M. Lunt, L. Wedderburn, K. Newell, A. Evans, G. Manning, C. Scaife, C. McAllister, S. R. Pennington, M. Duncan, T. Moore, C. Pericleous, S. C. Croca, I. Giles, K. Alber, H. Yong, A. Midgely, A. Rahman, M. Rzewuska, C. Mallen, V. Y. Strauss, J. Belcher, G. Peat, R. Byng-Maddick, M. Wijendra, H. Penn, E. Roddy, S. Muller, R. Hayward, F. Kamlow, A. Pakozdi, A. Jawad, D. J. Green, S. L. Hider, S. Singh Bawa, S. Bawa, A. Turton, M. Palmer, J. Lewis, T. Moss, C. E. Goodchild, N. Tang, D. Scott, P. Salkovskis, S. Selvan, L. Williamson, N. Thalayasingam, M. Higgins, V. Saravanan, M. Rynne, J. D. Hamilton, C. Heycock, C. Kelly, S. Norton, A. Sacker, J. Done, A. Young, J. S. Smolen, R. M. Fleischmann, P. Emery, R. F. van Vollenhoven, B. Guerette, S. Santra, H. Kupper, L. Redden, A. Kavanaugh, E. C. Keystone, D. van der Heijde, M. E. Weinblatt, N. Mozaffarian, S. Liu, N. Zhang, S. Wilkinson, M. Riaz, A. J. Ostor, M. K. Nisar, G. Burmester, X. Mariette, F. Navarro-Blasco, U. Oezer, S. Kary, K. Unnebrink, P. Jobanputra, F. Maggs, A. Deeming, D. Carruthers, E. Rankin, A. Jordan, A. Faizal, C. Goddard, M. Pugh, S. Bowman, S. Brailsford, P. Nightingale, N. Tugnet, S. C. Cooper, K. M. Douglas, C. S. Edwin Lim, S. Bee Lian Low, C. Joy, L. Hill, P. Davies, S. Mukherjee, P. Cornell, S. L. Westlake, S. Richards, F. Rahmeh, P. W. Thompson, F. Breedveld, E. Keystone, R. Landewe, M. McIlraith, C. Dharmapalaiah, L. Shand, G. Rose, R. Watts, A. Eldashan, B. Dasgupta, F. A. Borg, G. M. Bell, A. E. Anderson, R. A. Harry, J. N. Stoop, C. M. Hilkens, J. Isaacs, A. Dickinson, E. McColl, S. Banik, L. Smith, J. France, A. Rutherford, A. Scott Russell, J. Smith, I. Jassim, R. Withrington, P. Bacon, D. De Lord, L. McGregor, I. Morrison, A. Stirling, D. R. Porter, S. A. Saunders, S. Else, O. Semenova, H. Thompson, O. Ogunbambi, S. Kallankara, E. Baguley, Y. Patel, S. Alzabin, S. Abraham, T. E. Taher, A. Palfeeman, D. Hull, K. McNamee, E. Pathan, A. Kinderlerer, P. Taylor, R. O. Williams, R. A. Mageed, O. Iaremenko, G. Mikitenko, M. Ferrari, T. Kamalati, C. Pitzalis, F. Pearce, S. Tosounidou, K. Obrenovic, N. Erb, J. Packham, R. Sandhu, C. White, C. M. Cardy, E. Justice, M. Frank, L. Li, M. Lloyd, A. Ahmed, S. Readhead, A. Ala, M. Fittall, J. Manson, J. Sibilia, R. Marc Flipo, B. Combe, C. Gaillez, M. Le Bars, C. Poncet, A. Elegbe, R. Westhovens, R. Hassanzadeh, C. Mangan, R. Fleischmann, R. van Vollenhoven, T. W. J. Huizinga, R. Goldermann, B. Duncan, J. Timoshanko, K. Luijtens, O. Davies, M. Dougados, J. Hewitt, M. Owlia, M. Schiff, R. Alten, J. L. Kaine, P. T. Nash, I. Delaet, K. Qi, M. C. Genovese, J. Clark, S. Kardash, E. Wong, R. Hull, F. McCrae, R. Shaban, L. Thomas, S. Young-Min, J. Ledingham, A. Covarrubias Cobos, G. Leon, E. F. Mysler, M. W. Keiserman, R. M. Valente, J. Abraham Simon Campos, W. Porawska, J. H. Box, C. W. Legerton, E. L. Nasonov, P. Durez, R. Pappu, J. Teng, C. J. Edwards, N. Arden, J. Campbell, T. van Staa, C. Housden, I. Sargeant, E. Choy, S. McAuliffe, K. Roberts, P. Sarzi-Puttini, A. Andrianakos, T. P. Sheeran, D. Choquette, A. Finckh, M.-L. Desjuzeur, E. K. Gemmen, C. Mpofu, J.-E. Gottenberg, P. Shah, M. Cox, A. Nye, A. O'Brien, P. Jones, G. T. Jones, P. Paudyal, H. MacPherson, J. Sim, E. Ernst, M. Fisken, G. Lewith, J. Tadman, G. J. Macfarlane, P. Bertin, C. Arendt, I. Terpstra, B. VanLunen, M. de Longueville, H. Zhou, A. Cai, E. Lacy, J. Kay, E. Matteson, C. Hu, E. Hsia, M. Doyle, M. Rahman, D. Shealy, D. L. Scott, F. Ibrahim, H. Abozaid, A. Hassell, M. Plant, D. Walker, G. Simpson, A. Kowalczyk, P. Prouse, A. Brown, M. George, N. Kumar, K. Mackay, S. Marshall, C. L. Ludivico, B. Murthy, M. Corbo, W. Samborski, F. Berenbaum, J. Ambrugeat, B. Bennett, H. Burkhardt, V. Bykerk, J. Roman Ivorra, J. Wollenhaupt, A. Stancati, C. Bernasconi, D. G. I. Scott, P. Claydon, C. Ellis, S. Buchan, J. Pope, C. O. Bingham, E. M. Massarotti, G. Coteur, M. Weinblatt, C. Ball, T. Ainsworth, J. Kermik, J. Woodham, I. Haq, E. Quesada-Masachs, A. Carolina Diaz, G. Avila, I. Acosta, X. Sans, C. Alegre, S. Marsal, D. McWilliams, P. D. Kiely, R. Bolce, J. Wang, M. Ingham, R. Dehoratius, D. Decktor, V. Rao, A. Pavlov, M. Klearman, D. Musselman, J. Giles, J. Bathon, N. Sattar, J. Lee, D. Baxter, J. S. McLaren, M.-M. Gordon, K. Z. Thant, E. L. Williams, S. Earl, P. White, J. Williams, A. K. Jan, A. I. Bhatti, C. Stafford, M. Carolan, and S. A. Ramakrishnan

Subjects
medicine.medical_specialty, Comorbid anxiety, business.industry, Osteoarthritis, Primary care, medicine.disease, Rheumatology, Internal medicine, General practice, medicine, Anxiety, Pharmacology (medical), In patient, medicine.symptom, business, Depression (differential diagnoses)
Published
2012

24. New viral outbreaks: time for rheumatologists to get involved?

Author

Deshire Alpizar-Rodriguez, Axel Finckh, and Ilias Lazarou

Subjects
ddc:616, 030203 arthritis & rheumatology, 0301 basic medicine, medicine.medical_specialty, business.industry, Outbreak, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Rheumatology, medicine, Pharmacology (medical), Intensive care medicine, business
Published
2017

25. O07. First Results of a European Registries Collaborative Project to Describe the Spectrum of Lymphomas Across Different Drug Treatment Groups in Rheumatoid Arthritis

Author

Jakub Zavada, Johan Askling, Eva Baecklund, Lene Mellemkjær, Louise K. Mercer, Jacques Morel, Kimme L. Hyrich, Helena Canhão, Piet L. C. M. van Riel, Karin Hellgren, William G Dixon, Lene Dreyer, Fernando Martins, Axel Finckh, Joachim Listing, Angela Zink, Xavier Mariette, Jacques-Eric Gottenberg, Florence Tubach, Anja Strangfeld, Merete Lund Hetland, Florenzo Iannone, and Victoria Hernández

Subjects
Drug treatment, medicine.medical_specialty, Pharmacotherapy, business.industry, Rheumatoid arthritis, Internal medicine, medicine, Physical therapy, medicine.disease, business, Lymphoma
Abstract

First Results Of A European Registries Collaborative Project To Describe The Spectrum Of Lymphomas Across Different Drug Treatment Groups In Rheumatoid Arthritis

Published
2015

26. Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort.

Author

Alpizar-Rodriguez, Deshire, Förger, Frauke, Courvoisier, Delphine Sophie, Gabay, Cem, and Finckh, Axel

Subjects
RHEUMATOID arthritis risk factors, AGE distribution, FUNCTIONAL assessment, HORMONES, LIFE skills, LONGITUDINAL method, MENOPAUSE, SCIENTIFIC observation, QUESTIONNAIRES, RHEUMATOID arthritis, THERAPEUTICS, REPRODUCTIVE health, MULTIPLE regression analysis, EDUCATIONAL attainment, RETROSPECTIVE studies, POSTMENOPAUSE, DISEASE duration, DISEASE progression
Abstract

Objectives To study the relationship between female reproductive and menopausal factors on functional and structural joint damage progression in women with RA. Methods This is an observational cohort study of RA patients enrolled in the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. Information about female hormonal factors, such as pregnancies, menopause and hormonal therapy, were retrospectively retrieved using a specific questionnaire. The primary outcome was functional disability progression (HAQ) and the secondary outcome radiographic joint damage progression. We compared the functional progression between pre- and post-menopausal women using a multilevel regression model for longitudinal data, adjusting for potential confounders, such as baseline age, years of education, disease duration, seropositivity, DAS28 and treatment. Results A total of 1667 women were analysed, of whom 1025 (61%) were post-menopausal. Participants had a median of 6 HAQ assessments (interquartile range 3–10) during 5.1 (interquartile range 2.2–9.8) years of follow-up. At baseline, post-menopausal women had higher HAQ and erosion scores than pre-menopausal women. The evolution of HAQ scores over time differed between pre- and post-menopausal women (P < 0.001), with a less favourable evolution in post-menopausal women, particularly with earlier age at menopause. Erosion progression did not differ between pre- and post-menopausal women. Conclusion In women with RA, functional disability progression differed between pre- and post-menopausal women. The more favourable evolution of function in pre-menopausal women was not explained by disease duration, age or radiographic damage. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

29. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: Table 1

Author

Jacques-Eric Gottenberg, Andrea Rubbert-Roth, Florian Schuch, Ernest Choy, Frank Behrens, Daniel Aletaha, Axel Finckh, and Juan J. Gomez-Reino

Subjects
musculoskeletal diseases, 030203 arthritis & rheumatology, medicine.medical_specialty, Combination therapy, business.industry, Evidence-based medicine, Disease, Pharmacology, medicine.disease, Antirheumatic Agents, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Rheumatoid arthritis, medicine, Combined Modality Therapy, Pharmacology (medical), 030212 general & internal medicine, Intensive care medicine, Adverse effect, business, Contraindication
Abstract

Current EULAR guidelines state that biologic DMARD (bDMARD) therapy should be administered in combination with MTX or other conventional synthetic (cs) DMARD in RA. Nonetheless, a third of patients for whom a bDMARD agent is prescribed take it in the absence of concurrent csDMARD therapy. While the reasons underlying the low uptake of bDMARD-csDMARD combination therapy in clinical practice have not been well delineated, they may include poor adherence, contraindication to csDMARD therapy and adverse effects, as well as csDMARD withdrawal following remission. The challenges surrounding bDMARD therapy and the benefit/risk ratio of biologic monotherapy when compared with combination with a csDMARD will be discussed. We will provide insights into these important issues, as well as reviewing the evidence base differentiating biologic agents and exploring therapeutic options for patients with rheumatoid arthritis for whom csDMARD therapy is contraindicated or discontinued.

Published
2016

30. 87. Comparative Efficacy of Novel Disease-Modifying Antirheumatic Drugs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Traditional Dmards: A Network Meta-Analysis

Author

Felicity Buckley, Fred Dejonckheere, Tom W J Huizinga, Jeroen P. Jansen, and Axel Finckh

Subjects
medicine.medical_specialty, business.industry, Disease, medicine.disease, Rheumatology, Rheumatoid arthritis, Internal medicine, Meta-analysis, medicine, Pharmacology (medical), Methotrexate, business, Antirheumatic drugs, medicine.drug
Published
2014

31. The role of female hormonal factors in the development of rheumatoid arthritis.

Author

Alpízar-Rodríguez, Deshiré, Pluchino, Nicola, Canny, Geraldine, Gabay, Cem, and Finckh, Axel

Subjects
RHEUMATOID arthritis risk factors, ANDROGENS, ESTROGEN, SEX hormones, PROGESTERONE, RHEUMATOID arthritis, SEX distribution, WOMEN'S health
Abstract

RA is the most common chronic systemic autoimmune disease, with a higher prevalence in women, suggesting female hormonal factors play a role in the development of the disease. However, many controversies still exist. The aim of this review was to appraise data from recent research concerning female hormonal factors and their association with RA disease development. The study of female hormonal factors is challenging because serum levels may differ throughout a woman's lifetime and interact with various environmental, immunological, genetic and endocrine factors influencing the development of autoimmunity. As some female hormonal factors may be potentially modifiable, understanding their impact on RA development is clinically relevant and may result in specific preventive interventions in high-risk populations. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

32. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Author

Choy, Ernest, Aletaha, Daniel, Behrens, Frank, Finckh, Axel, Gomez-Reino, Juan, Gottenberg, Jacques-Eric, Schuch, Florian, and Rubbert-Roth, Andrea

Subjects
ANTIRHEUMATIC agents, COMBINATION drug therapy, RHEUMATOID arthritis, THERAPEUTICS
Abstract

Current EULAR guidelines state that biologic DMARD (bDMARD) therapy should be administered in combination with MTX or other conventional synthetic (cs) DMARD in RA. Nonetheless, a third of patients for whom a bDMARD agent is prescribed take it in the absence of concurrent csDMARD therapy. While the reasons underlying the low uptake of bDMARD-csDMARD combination therapy in clinical practice have not been well delineated, they may include poor adherence, contraindication to csDMARD therapy and adverse effects, as well as csDMARD withdrawal following remission. The challenges surrounding bDMARD therapy and the benefit/risk ratio of biologic monotherapy when compared with combination with a csDMARD will be discussed. We will provide insights into these important issues, as well as reviewing the evidence base differentiating biologic agents and exploring therapeutic options for patients with rheumatoid arthritis for whom csDMARD therapy is contraindicated or discontinued. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

34. Muscle disorders * 111. The impact of fatigue in patients with idiopathic inflammatory myopathy: a mixed method study

Author

Campbell, R., primary, Hofmann, D., additional, Hatch, S., additional, Gordon, P., additional, Lempp, H., additional, Das, L., additional, Blumbergs, P., additional, Limaye, V., additional, Vermaak, E., additional, McHugh, N., additional, Edwards, M. H., additional, Jameson, K., additional, Sayer, A. A., additional, Dennison, E., additional, Cooper, C., additional, Salvador, F. B., additional, Huertas, C., additional, Isenberg, D., additional, Jackson, E. J., additional, Middleton, A., additional, Churchill, D., additional, Walker-Bone, K., additional, Worsley, P. R., additional, Mottram, S., additional, Warner, M., additional, Morrissey, D., additional, Gadola, S., additional, Carr, A., additional, Stokes, M., additional, Srivastava, R. N., additional, Sanghi, D., additional, Elbaz, A., additional, Mor, A., additional, Segal, G., additional, Drexler, M., additional, Norman, D., additional, Peled, E., additional, Rozen, N., additional, Goryachev, Y., additional, Debbi, E. M., additional, Haim, A., additional, Wolf, A., additional, Debi, R., additional, Cohen, M. S., additional, Igolnikov, I., additional, Bar Ziv, Y., additional, Benkovich, V., additional, Bernfeld, B., additional, Collins, J., additional, Moots, R. J., additional, Clegg, P. D., additional, Milner, P. I., additional, Ejtehadi, H. D., additional, Nelson, P. N., additional, Wenham, C., additional, Balamoody, S., additional, Hodgson, R., additional, Conaghan, P., additional, Wilkie, R., additional, Blagojevic, M., additional, Jordan, K. P., additional, Mcbeth, J., additional, Peffers, M. J., additional, Beynon, R. J., additional, Thornton, D. J., additional, Chapman, R., additional, Chapman, V., additional, Walsh, D., additional, Kelly, S., additional, Hui, M., additional, Zhang, W., additional, Doherty, S., additional, Rees, F., additional, Muir, K., additional, Maciewicz, R., additional, Doherty, M., additional, Snelling, S., additional, Davidson, R. K., additional, Swingler, T., additional, Price, A., additional, Clark, I., additional, Stockley, E., additional, Hathway, G., additional, Faas, H., additional, Auer, D., additional, Hirsch, G., additional, Hale, E., additional, Kitas, G., additional, Klocke, R., additional, Abraham, A., additional, Pearce, M. S., additional, Mann, K. D., additional, Francis, R. M., additional, Birrell, F., additional, Tucker, M., additional, Mellon, S. J., additional, Jones, L., additional, Price, A. J., additional, Dieppe, P. A., additional, Gill, H. S., additional, Ashraf, S., additional, Walsh, D. A., additional, McCollum, D., additional, McCabe, C., additional, Grieve, S., additional, Shipley, J., additional, Gorodkin, R., additional, Oldroyd, A. G., additional, Evans, B., additional, Greenbank, C., additional, Bukhari, M., additional, Rajak, R., additional, Bennett, C., additional, Williams, A., additional, Martin, J. C., additional, Abdulkader, R., additional, MacNicol, C., additional, Brixey, K., additional, Stephenson, S., additional, Clunie, G., additional, Andrews, R. N., additional, Clark, E. M., additional, Gould, V. C., additional, Carter, L., additional, Morrison, L., additional, Tobias, J. H., additional, Pye, S. R., additional, Vanderschueren, D., additional, O'Neill, T. W., additional, Lee, D. M., additional, Jans, I., additional, Billen, J., additional, Gielen, E., additional, Laurent, M., additional, Claessens, F., additional, Adams, J. E., additional, Ward, K. A., additional, Bartfai, G., additional, Casanueva, F., additional, Finn, J. D., additional, Forti, G., additional, Giwercman, A., additional, Han, T. S., additional, Huhtaniemi, I., additional, Kula, K., additional, Lean, M. E., additional, Pendleton, N., additional, Punab, M., additional, Wu, F. C., additional, Boonen, S., additional, Mercieca, C., additional, Webb, J., additional, Bhalla, A., additional, Fairbanks, S., additional, Moss, K. E., additional, Collins, C., additional, Sedgwick, P., additional, Parker, J., additional, Harvey, N. C., additional, Cole, Z. A., additional, Crozier, S. R., additional, Ntani, G., additional, Mahon, P. A., additional, Robinson, S. M., additional, Inskip, H. M., additional, Godfrey, K. M., additional, Dennison, E. M., additional, Bridges, M., additional, Ruddick, S., additional, Holroyd, C. R., additional, Mahon, P., additional, Godfrey, K., additional, McNeilly, T., additional, McNally, C., additional, Beringer, T., additional, Finch, M., additional, Coda, A., additional, Davidson, J., additional, Walsh, J., additional, Fowlie, P., additional, Carline, T., additional, Santos, D., additional, Patil, P., additional, Rawcliffe, C., additional, Olaleye, A., additional, Moore, S., additional, Fox, A., additional, Sen, D., additional, Ioannou, Y., additional, Nisar, S., additional, Rankin, K., additional, Birch, M., additional, Finnegan, S., additional, Rooney, M., additional, Gibson, D. S., additional, Malviya, A., additional, Ferris, C. M., additional, Rushton, S. P., additional, Foster, H. E., additional, Hanson, H., additional, Muthumayandi, K., additional, Deehan, D. J., additional, Birt, L., additional, Poland, F., additional, MacGregor, A., additional, Armon, K., additional, Pfeil, M., additional, McErlane, F., additional, Beresford, M. W., additional, Baildam, E. M., additional, Thomson, W., additional, Hyrich, K., additional, Chieng, A., additional, Gardner-Medwin, J., additional, Lunt, M., additional, Wedderburn, L., additional, Newell, K., additional, Evans, A., additional, Manning, G., additional, Scaife, C., additional, McAllister, C., additional, Pennington, S. R., additional, Duncan, M., additional, Moore, T., additional, Pericleous, C., additional, Croca, S. C., additional, Giles, I., additional, Alber, K., additional, Yong, H., additional, Midgely, A., additional, Rahman, A., additional, Rzewuska, M., additional, Mallen, C., additional, Strauss, V. Y., additional, Belcher, J., additional, Peat, G., additional, Byng-Maddick, R., additional, Wijendra, M., additional, Penn, H., additional, Roddy, E., additional, Muller, S., additional, Hayward, R., additional, Kamlow, F., additional, Pakozdi, A., additional, Jawad, A., additional, Green, D. J., additional, Hider, S. L., additional, Singh Bawa, S., additional, Bawa, S., additional, Turton, A., additional, Palmer, M., additional, Lewis, J., additional, Moss, T., additional, Goodchild, C. E., additional, Tang, N., additional, Scott, D., additional, Salkovskis, P., additional, Selvan, S., additional, Williamson, L., additional, Thalayasingam, N., additional, Higgins, M., additional, Saravanan, V., additional, Rynne, M., additional, Hamilton, J. D., additional, Heycock, C., additional, Kelly, C., additional, Norton, S., additional, Sacker, A., additional, Done, J., additional, Young, A., additional, Smolen, J. S., additional, Fleischmann, R. M., additional, Emery, P., additional, van Vollenhoven, R. F., additional, Guerette, B., additional, Santra, S., additional, Kupper, H., additional, Redden, L., additional, Kavanaugh, A., additional, Keystone, E. C., additional, van der Heijde, D., additional, Weinblatt, M. E., additional, Mozaffarian, N., additional, Liu, S., additional, Zhang, N., additional, Wilkinson, S., additional, Riaz, M., additional, Ostor, A. J., additional, Nisar, M. K., additional, Burmester, G., additional, Mariette, X., additional, Navarro-Blasco, F., additional, Oezer, U., additional, Kary, S., additional, Unnebrink, K., additional, Jobanputra, P., additional, Maggs, F., additional, Deeming, A., additional, Carruthers, D., additional, Rankin, E., additional, Jordan, A., additional, Faizal, A., additional, Goddard, C., additional, Pugh, M., additional, Bowman, S., additional, Brailsford, S., additional, Nightingale, P., additional, Tugnet, N., additional, Cooper, S. C., additional, Douglas, K. M., additional, Edwin Lim, C. S., additional, Bee Lian Low, S., additional, Joy, C., additional, Hill, L., additional, Davies, P., additional, Mukherjee, S., additional, Cornell, P., additional, Westlake, S. L., additional, Richards, S., additional, Rahmeh, F., additional, Thompson, P. W., additional, Breedveld, F., additional, Keystone, E., additional, Landewe, R., additional, McIlraith, M., additional, Dharmapalaiah, C., additional, Shand, L., additional, Rose, G., additional, Watts, R., additional, Eldashan, A., additional, Dasgupta, B., additional, Borg, F. A., additional, Bell, G. M., additional, Anderson, A. E., additional, Harry, R. A., additional, Stoop, J. N., additional, Hilkens, C. M., additional, Isaacs, J., additional, Dickinson, A., additional, McColl, E., additional, Banik, S., additional, Smith, L., additional, France, J., additional, Rutherford, A., additional, Scott Russell, A., additional, Smith, J., additional, Jassim, I., additional, Withrington, R., additional, Bacon, P., additional, De Lord, D., additional, McGregor, L., additional, Morrison, I., additional, Stirling, A., additional, Porter, D. R., additional, Saunders, S. A., additional, Else, S., additional, Semenova, O., additional, Thompson, H., additional, Ogunbambi, O., additional, Kallankara, S., additional, Baguley, E., additional, Patel, Y., additional, Alzabin, S., additional, Abraham, S., additional, Taher, T. E., additional, Palfeeman, A., additional, Hull, D., additional, McNamee, K., additional, Pathan, E., additional, Kinderlerer, A., additional, Taylor, P., additional, Williams, R. O., additional, Mageed, R. A., additional, Iaremenko, O., additional, Mikitenko, G., additional, Ferrari, M., additional, Kamalati, T., additional, Pitzalis, C., additional, Pearce, F., additional, Tosounidou, S., additional, Obrenovic, K., additional, Erb, N., additional, Packham, J., additional, Sandhu, R., additional, White, C., additional, Cardy, C. M., additional, Justice, E., additional, Frank, M., additional, Li, L., additional, Lloyd, M., additional, Ahmed, A., additional, Readhead, S., additional, Ala, A., additional, Fittall, M., additional, Manson, J., additional, Sibilia, J., additional, Marc Flipo, R., additional, Combe, B., additional, Gaillez, C., additional, Le Bars, M., additional, Poncet, C., additional, Elegbe, A., additional, Westhovens, R., additional, Hassanzadeh, R., additional, Mangan, C., additional, Fleischmann, R., additional, van Vollenhoven, R., additional, Huizinga, T. W. J., additional, Goldermann, R., additional, Duncan, B., additional, Timoshanko, J., additional, Luijtens, K., additional, Davies, O., additional, Dougados, M., additional, Hewitt, J., additional, Owlia, M., additional, Schiff, M., additional, Alten, R., additional, Kaine, J. L., additional, Nash, P. T., additional, Delaet, I., additional, Qi, K., additional, Genovese, M. C., additional, Clark, J., additional, Kardash, S., additional, Wong, E., additional, Hull, R., additional, McCrae, F., additional, Shaban, R., additional, Thomas, L., additional, Young-Min, S., additional, Ledingham, J., additional, Covarrubias Cobos, A., additional, Leon, G., additional, Mysler, E. F., additional, Keiserman, M. W., additional, Valente, R. M., additional, Abraham Simon Campos, J., additional, Porawska, W., additional, Box, J. H., additional, Legerton, C. W., additional, Nasonov, E. L., additional, Durez, P., additional, Pappu, R., additional, Teng, J., additional, Edwards, C. J., additional, Arden, N., additional, Campbell, J., additional, van Staa, T., additional, Housden, C., additional, Sargeant, I., additional, Choy, E., additional, McAuliffe, S., additional, Roberts, K., additional, Sarzi-Puttini, P., additional, Andrianakos, A., additional, Sheeran, T. P., additional, Choquette, D., additional, Finckh, A., additional, Desjuzeur, M.-L., additional, Gemmen, E. K., additional, Mpofu, C., additional, Gottenberg, J.-E., additional, Shah, P., additional, Cox, M., additional, Nye, A., additional, O'Brien, A., additional, Jones, P., additional, Jones, G. T., additional, Paudyal, P., additional, MacPherson, H., additional, Sim, J., additional, Ernst, E., additional, Fisken, M., additional, Lewith, G., additional, Tadman, J., additional, Macfarlane, G. J., additional, Bertin, P., additional, Arendt, C., additional, Terpstra, I., additional, VanLunen, B., additional, de Longueville, M., additional, Zhou, H., additional, Cai, A., additional, Lacy, E., additional, Kay, J., additional, Matteson, E., additional, Hu, C., additional, Hsia, E., additional, Doyle, M., additional, Rahman, M., additional, Shealy, D., additional, Scott, D. L., additional, Ibrahim, F., additional, Abozaid, H., additional, Hassell, A., additional, Plant, M., additional, Walker, D., additional, Simpson, G., additional, Kowalczyk, A., additional, Prouse, P., additional, Brown, A., additional, George, M., additional, Kumar, N., additional, Mackay, K., additional, Marshall, S., additional, Ludivico, C. L., additional, Murthy, B., additional, Corbo, M., additional, Samborski, W., additional, Berenbaum, F., additional, Ambrugeat, J., additional, Bennett, B., additional, Burkhardt, H., additional, Bykerk, V., additional, Roman Ivorra, J., additional, Wollenhaupt, J., additional, Stancati, A., additional, Bernasconi, C., additional, Scott, D. G. I., additional, Claydon, P., additional, Ellis, C., additional, Buchan, S., additional, Pope, J., additional, Bingham, C. O., additional, Massarotti, E. M., additional, Coteur, G., additional, Weinblatt, M., additional, Ball, C., additional, Ainsworth, T., additional, Kermik, J., additional, Woodham, J., additional, Haq, I., additional, Quesada-Masachs, E., additional, Carolina Diaz, A., additional, Avila, G., additional, Acosta, I., additional, Sans, X., additional, Alegre, C., additional, Marsal, S., additional, McWilliams, D., additional, Kiely, P. D., additional, Bolce, R., additional, Wang, J., additional, Ingham, M., additional, Dehoratius, R., additional, Decktor, D., additional, Rao, V., additional, Pavlov, A., additional, Klearman, M., additional, Musselman, D., additional, Giles, J., additional, Bathon, J., additional, Sattar, N., additional, Lee, J., additional, Baxter, D., additional, McLaren, J. S., additional, Gordon, M.-M., additional, Thant, K. Z., additional, Williams, E. L., additional, Earl, S., additional, White, P., additional, Williams, J., additional, Jan, A. K., additional, Bhatti, A. I., additional, Stafford, C., additional, Carolan, M., additional, and Ramakrishnan, S. A., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results